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Abstract
AIM: To assess whether video capsule endoscopy (VCE) 
affects the outcomes of left ventricular assist devices 
(LVADs) recipients with gastrointestinal bleeding.
METHODS: This is a retrospective study of LVAD 
recipients with obscure gastrointestinal bleeding 
(OGIB) who underwent VCE at a tertiary medical 
center between 2005 and 2013. All patients were 
admitted and monitored with telemetry and all VCE and 
subsequent endoscopic procedures were performed 
as inpatients. A VCE study was considered positive 
only when P2 lesions were found and was regarded as 
negative if P1 or P0 were identified. All patients were 
followed until heart transplant, death, or the end of the 
study.
RESULTS: Between 2005 and 2013, 30 patients 
with LVAD underwent VCE. Completion rate of VCE 
was 93.3% and there was no capsule retention. No 
interference of VCE recording or the function of LVAD 
was found. VCE was positive in 40% of patients 
(n  = 12). The most common finding was active 
small intestinal bleeding (50%) and small intestinal 
angiodysplasia (33.3%). There was no difference in 
the rate of recurrent bleeding between patients with 
positive and negative VCE study (50.0% vs  55.6%, 
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P  = 1.00) during an average of 11.6 ± 9.6 mo follow 
up. Among patients with positive VCE, the recurrent 
bleeding rate did not differ whether subsequent 
endoscopy was performed (50% vs  50%, P  = 1.00).
CONCLUSION: VCE can be safely performed in LVAD 
recipients with a diagnostic yield of 40%. VCE does not 
affect recurrent bleeding in LVAD patients regardless of 
findings.
Key words: Heart-assist devices; Capsule endoscopy; 
Gastrointestinal hemorrhage; Heart failure; Endoscopy; 
Digestive system
© The Author(s) 2016. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Obscure gastrointestinal bleeding (OGIB) 
is a common complication for patients receiving left 
ventricular assist device (LVAD). Although video capsule 
endoscopy (VCE) is frequently used to investigate 
OGIB, there is limited data on the safety and usefulness 
of VCE in LVAD recipients. We found that VCE can be 
safely performed in LVAD recipients with OGIB and 
with a 40% diagnostic yield. However, the results of 
VCE and the subsequent management driven by VCE 
did not affect the rate of recurrent GIB. Endoscopic 
intervention thus should be used judiciously, and 
alternative ways of management should be considered 
in LVAD patients with OGIB.
Amornsawadwattana S, Nassif M, Raymer D, LaRue S, Chen 
CH. Video capsule endoscopy in left ventricular assist device 
recipients with obscure gastrointestinal bleeding. World J 
Gastroenterol 2016; 22(18): 4559-4566  Available from: URL: 
http://www.wjgnet.com/1007-9327/full/v22/i18/4559.htm  DOI: 
http://dx.doi.org/10.3748/wjg.v22.i18.4559
INTRODUCTION
Approximately 50000 patients die from advanced 
heart failure in the United States each year, with a 
high mortality rate and life expectancy < 2 years when 
only medical therapies are utilized[1]. Although heart 
transplantation is a definitive therapeutic option for 
advanced heart failure, only 2200 heart transplants 
are performed annually due to donor shortage, 
leaving a large proportion of heart failure patients 
in need of an alternative therapy[2]. In recent years, 
Left Ventricular Assist Devices (LVADs) are used 
increasingly in this setting as destination therapy, 
bridge to transplantation, bridge to recovery, or bridge 
to decision in patients with advanced heart failure[3]. 
This approach has increased survival and improved 
quality of life in advanced heart failure patients[4].
Since the initial introduction of LVAD therapy, it 
is well documented that LVADs increase the risk of 
gastrointestinal bleeding (GIB), with as many as 
20%-40% of LVAD recipients manifesting GIB[5-7]. 
The mechanism of GIB in LVAD recipients remains 
incompletely understood, but it is thought to be 
contributed to by development of angiodysplasia, 
acquired von Willebrand disease, persistent right 
ventricular dysfunction, and mucosal ischemia 
secondary to low pulse pressure[8,9]. GIB is further 
exacerbated by the use of anticoagulation in LVAD 
patients. Although previous reports found that upper 
GI tract is the most common site of GIB in LVAD 
recipients[10], obscure gastrointestinal bleeding (OGIB) 
remains a frustrating condition frequently encountered 
in this population.
Video capsule endoscopy (VCE) has made a 
significant impact on the evaluation of patients 
with OGIB, with a diagnostic yield of approximately 
60%-70%[11]. However, it is a relative contraindication 
to use VCE in the setting of implanted electrical 
medical devices[12], and there is limited data on both 
the usage of VCE in LVAD associated OGIB, as well as 
the safety of VCE in LVAD patients[13-19].
We retrospectively evaluated our experience with 
VCE in LVAD patients with OGIB. The aims of our 
study were to determine the safety and diagnostic 
yield of VCE, and to assess the outcomes based on 
management driven by VCE in LVAD recipients.
MATERIALS AND METHODS
Patients
All patients undergoing VCE following implantation 
of LVAD at Washington University Medical Center 
between January 2005 and September 2013 were 
eligible for inclusion in this retrospective study. For 
inclusion, all subjects were required to have obscure GI 
bleeding, which was defined as hematemesis, melena, 
hematochezia, or anemia with positive fecal occult 
blood, without a definitive source identified on upper 
endoscopy (EGD) and colonoscopy, thereby requiring 
VCE for further localization of the bleeding source. 
Exclusion criteria consisted of patients aged less 
than 18 years, patients who did not have both EGD 
and colonoscopy performed prior to VCE, incomplete 
data collection and studies with unintelligible data. 
This study protocol was approved by the Institutional 
Review Board at Washington University in St. Louis.
Data collection
Inpatient and outpatient charts were reviewed in 
the institution’s electronic medical records to extract 
demographic data, indications for LVAD, types of 
LVAD implanted, follow-up and GIB data. Patients 
were followed until heart transplant, death or the last 
point of contact in the electronic medical records. 
Patients lost to follow up were not included in the final 
analyses. Episodes of recurrent GIB were identified 
and recorded. Recurrent GIB was defined as any 
recurrence of overt GIB or anemia with positive 
fecal occult blood. Medical records were reviewed to 
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determine cause of death, and to determine if death 
was related to GIB when relevant. The Charlson 
comorbidity index was calculated based on the review 
of medical records[20].
Procedures
All VCE studies were performed using PillCam (Given 
Imaging, Duluth, GA, United States) as inpatients. 
The risk of capsule retention was assessed by history 
and radiological imaging studies such as small bowel 
follow-through or CT enterography per the discretion of 
GI consult service. Patients were given a half gallon of 
Golytely (Braintree Laboratories, Braintree, MA, United 
States) the evening before the procedure and were 
kept nothing by mouth after midnight. On the day of 
the procedure, the capsule endoscope was ingested or 
endoscopically placed in the duodenum if patients had 
dysphagia or delayed gastric emptying. Patients were 
monitored by continuous telemetry and evaluated 
serially by staff. LVADs were monitored continuously 
by the system controller and interrogated immediately 
after the VCE via the system monitor to evaluate for 
any changes in function. VCE reports were evaluated 
for possible LVAD interference and medical records 
were evaluated for possible LVAD dysfunction related 
to VCE interference.
Outcomes
The findings on VCE were categorized into 3 types of 
mucosal abnormalities as previously reported[21]. P0 
lesions were those considered to have no bleeding 
potential such as normal study, submucosal vein, 
diverticula without bleeding, or nodule without mucosal 
break. P1 lesions were those having uncertain bleeding 
potential such as erosions or red spots. P2 lesions were 
those thought to have high bleeding potential such 
as ulcers, angiodysplasias, tumors, as well as active 
bleeding without lesions identified. The diagnostic 
yield of the study was assessed by the frequency of 
P2 lesions. Positive VCE studies were defined as VCE 
findings with P2 lesions. VCE findings reported P0 or 
P1 lesions were considered as negative VCE studies. If 
VCE did not reach the cecum at the end of recording, it 
was considered an incomplete study. Safety endpoints 
included interference of VCE with LVAD function, 
interference of LVAD with VCE reports, and other 
previously described adverse events associated with 
VCE.
Statistical analysis
For statistical analysis, data is reported as mean ± 
SD unless otherwise indicated. Fisher’s exact test and 
Student’s t-test were used for categorical variables and 
continuous variables, respectively. A p-value less than 
0.05 was required for statistical significance. Logistic 
regression was used to examine predictors for VCE 
outcomes.
RESULTS
Thirty LVAD patients underwent VCE over the 8-year 
study period. No patient was lost to follow up or 
excluded in this study. All patients were treated and all 
procedures were performed as inpatients. The mean 
age was 60.1 ± 10.2 years, and 20% of patients were 
female (Table 1). Thoratec HeartMate Ⅱ LVADs were 
implanted in all of the patients except one patient who 
had a HeartWare HVAD. The Charlson comorbidity 
index, the history of GIB prior to LVAD implantation, 
the interval between LVAD implantation and GIB, and 
the history of overt GIB did not differ between patients 
with positive vs negative VCE studies. Twenty-three 
out of the thirty patients (76.7%) presented with overt 
OGIB: 21 with melena (70%), 2 with hematochezia 
(6.7%); whereas 7 patients (23.3%) presented with 
occult OGIB. Most of our patients received antiplatelets 
(86.7%) or anticoagulants (93.3%) on presentation. 
On average 3.2 ± 1.7 endoscopic procedures were 
performed within 4.1 ± 5.0 d prior to VCE, including 
37 EGDs, 17 push enteroscopies, 40 colonoscopies, 
4561 May 14, 2016|Volume 22|Issue 18|WJG|www.wjgnet.com
Table 1  Characteristics and outcomes of left ventricular assist device recipients undergoing video capsule endoscopy  n  (%)
Total, n  = 30 Positive study, n  = 12 Negative study, n  = 18 P value
Age (yr) 60.1 ± 10.2 62.6 ± 8.8 58.4 ± 10.9 0.27
Female   6 (20.0) 4 (33.3)   2 (11.1) 0.18
Charlson comorbidity index 4.7 5 4.6 0.70
History of GIB prior to LVAD   3 (10.0)   2 (16.7) 1 (5.6) 0.55
LVAD implant to GIB (mo)   4.8 ± 6.0 5.5 ± 7.0   4.4 ± 5.3 0.65
Overt GIB 23 (76.7)   8 (66.7) 15 (83.3) 0.39
Antiplatelet agents 26 (86.7) 10 (83.3) 16 (88.9) 1.00
Anticoagulants 28 (93.3) 11 (91.7) 17 (94.4) 1.00
Endoscopies prior to VCE (number)   3.2 ± 1.7 3.5 ± 1.9   3.0 ± 1.7 0.46
Length of stay (d)   13.1 ± 12.5 20.3 ± 17.6   8.3 ± 2.3 0.04
Follow-up (mo) 11.6 ± 9.6 9.2 ± 9.3 13.2 ± 9.7 0.28
Recurrent GIB rate 16 (53.3) 6 (50) 10 (55.6) 1.00
Endoscopies after VCE (number)   1.7 ± 2.2 1.8 ± 1.8 1.7 ± 2.5 0.97
Mortality rate 10 (33.3)   4 (33.3)   6 (33.3) 0.90
GIB: Gastrointestinal bleeding; LVAD: Left ventricular assist device; VCE: Video capsule endoscopy.
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angiodysplasias (33.3%). Eighteen VCE studies (60%) 
were negative, including 13 P0 lesions (12 normal, 1 
small nodule) and 5 P1 lesions (red spots). The only 
patient who had a HeartWare HVAD implanted had 
a normal VCE study. Despite prior negative upper 
endoscopies performed 2 and 24 d prior to VCE, two 
lesions were found within reach of EGD by VCE: one 
gastric ulcer and one duodenal angiodysplasia (neither 
VCE was placed endoscopically). One VCE found active 
bleeding in the colon without the cause of bleeding 
identified. Angiodysplasia were found in 4 patients: 
1 in the duodenum and 3 in the small intestine. In 2 
patients where VCE failed to reach the cecum at the 
end of recording, VCE still detected the cause of GIB: 
one with gastric ulcer and one with small intestine 
angiodysplasia. Using logistic regression, we found 
that higher INR on presentation was associated with 
a higher probability of positive findings in VCE (OR = 
3.62, 95%CI: 1.03-12.7, p = 0.04), adjusted for age, 
gender, and hemoglobin level.
Positive VCE studies led to further endoscopic 
evaluations in 6 patients out of 12 (50%): 6 push 
endoscopies and 3 single balloon enteroscopies. The 
other 6 patients with positive VCE did not have further 
endoscopies because they had no further bleeding and 
their hemoglobin had stabilized. During follow-up the 
overall recurrent bleeding rate in patients with positive 
VCE was 50% (6 out of 12). In addition, there was 
no difference in the recurrent bleeding rate whether 
subsequent endoscopic procedures were performed 
following positive VCE (3 out of 6 or 50% in each 
group, p = 1.00). Furthermore, after VCE, medications 
were adjusted in 7 out of 12 patients with positive 
VCE, and 8 out of 18 patients with negative VCE. 
These changes included discontinuation or decrease 
in the dose of aspirin and initiation of proton pump 
inhibitors. The change of medical management did 
not affect the rate of recurrent bleeding regardless of 
whether patients had a positive VCE (40% vs 57.1%, 
p = 1.00), or negative VCE (60% vs 50%, p = 1.00). 
The presentations of recurrent GIB were melena (n 
= 4), hematochezia (n = 1) and anemia with positive 
fecal occult blood (n = 1). The clinical course and 
management of LVAD recipients with positive VCE 
studies are detailed in Table 3. 
DISCUSSION
In this retrospective study spanning 8 years, we 
demonstrated the safety of VCE and a 40% diagnostic 
yield of P2 lesions in LVAD recipients with OGIB. We 
found that the results of VCE were not associated with 
the rate of recurrent GIB, the number of endoscopic 
procedures performed, or mortality rate. In addition, 
the findings of VCE and the subsequent management 
did not affect the rate of recurrent GIB in LVAD 
patients.
This study identified 30 LVAD recipients undergoing 
and 2 sigmoidoscopies. VCE was performed 6.2 ± 
2.6 d after the presentation of GIB. VCE was placed 
endoscopically in 2 patients (6.7%) because one 
patient had a history of pyloric stenosis, and the other 
patient failed the swallow study. The mean small bowel 
transit time of VCE was 3.2 ± 1.1 h. VCE did not reach 
the cecum in 2 patients (6.7%) over the 8 h recording 
period, but there was no capsule retention. There was 
no electromagnetic interference of either VCE or LVAD 
identified in any patients.
Patients with positive VCE study stayed in the 
hospital longer than patients with negative VCE study 
(20.3 d vs 8.3 d, p = 0.04). Over the average 11.6 mo 
follow-up period, there was no statistically significant 
difference in the recurrent bleeding rate (50% vs 
55.6%, p = 1.00), the number of endoscopies 
performed after VCE (1.8 ± 1.8 vs 1.7 ± 2.5, p = 0.97), 
or mortality rate (33.3% vs 33.3%, p = 0.90) between 
patients with positive and negative VCE. The total 
recurrent bleeding rate in this population was 53.3% (n 
= 16) and the presentation included melena (n = 12), 
hematochezia (n = 3) and anemia with positive fecal 
occult blood (n = 1). All 16 patients with recurrent 
bleeding were hospitalized and underwent transfusion 
and endoscopic procedures for managing recurrent 
GIB. The overall mortality rate in this study was 33.3% 
(n = 10): 7 patients died from underlying heart failure, 
2 patients died from septic shock, one patient died 
from subdural hematoma, and none of the patients 
died from GIB. Four LVAD recipients underwent heart 
transplantation on average 4.3 mo after VCE and 
did not develop recurrent GIB afterwards. Before 
heart transplantation, VCE studies were positive in 
2 patients (1 duodenal angiodysplasia and 1 jejunal 
angiodysplasia) and negative in 2 others. 
The diagnostic yield of VCE to detect P2 lesions 
in this study was 40%. Table 2 demonstrates the 
locations and the findings of positive VCE studies. Small 
intestine was the most common site of positive VCE 
findings (75%). The predominant positive VCE findings 
in our study were small intestinal bleeding with no 
source or lesion identified (50%) and small intestinal 
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Table 2  Locations and findings of positive video capsule 
endoscopy studies  n  (%)
Patients (n  = 12)
Locations of positive VCE findings
   Stomach and duodenum   2 (16.7)
   Small intestine   9 (75.0)
   Colon 1 (8.3)
Findings of positive VCE studies
   Small intestinal bleeding with no source or lesion 
   identified (2 in the duodenum, 4 in the jejunum)
  6 (50.0)
   Angiodysplasia (1 in the duodenum, 3 in the small 
   bowel)
  4 (33.3)
   Colonic bleeding with no source or lesion identified 1 (8.3)
   Gastric ulcer 1 (8.3)
VCE: Video capsule endoscopy. 
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VCE for OGIB. To our knowledge, this is the largest 
available series of VCE in LVAD patients in the 
literature[6,13-19,22] (Table 4). Our results show that 
VCE is safe to perform in LVAD recipients, without 
interference between VCE and LVAD and without 
capsule retention. One prior study found 2 cases of 
LVAD possibly interfering with capsule images, and 
suggested that the leads of VCE be placed away 
from LVAD[23]. Based on the results of this and other 
previous studies, the interference between VCE 
and LVAD is uncommon[14,16,23]. Consistent with our 
experience, a recent review article reported that VCE is 
unlikely to impair the function of cardiac pacemakers, 
implantable cardioverter defibrillators, and LVAD, 
although the authors cautioned that wireless telemetry 
may interfere with VCE recordings[24]. 
The diagnostic yield of VCE in LVAD patients in two 
previous reports was 31% (n = 13) and 80% (n = 
5) (Table 4)[6,22]. With a larger sample size of 30, the 
diagnostic yield in our study is 40%. Since only P2 
lesions were considered positive, our diagnostic yield 
reflects true clinically relevant findings. It is known 
that the diagnostic yield of VCE is higher when it is 
performed closer to the presenting GIB event[25,26], or 
in patients with overt GIB than with occult GIB[27,28]. 
It is also known that the diagnostic yield of VCE is 
comparable to double balloon enteroscopy (DBE) 
according to a meta-analysis[29]. A recent study of 
DBE in LVAD recipients who presented with overt 
OGIB found that the diagnostic yield of DBE was 
69% when DBE was performed within 24 h of initial 
presentation[30]. We suspect that VCE would have a 
similar diagnostic yield if it is performed within 24 h 
of overt OGIB. In our study, VCE was performed on 
average 6.2 d after admission- after coagulopathy was 
corrected and after other endoscopic procedures failed 
to identify the cause of OGIB. Using logistic regression, 
we found that higher INR on presentation was 
associated with a higher probability of positive VCE. 
If OGIB is highly suspected in an LVAD patient with 
a supra-therapeutic INR on presentation, expediting 
VCE, possibly before coagulopathy is corrected and 
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Table 3  Clinical course and management of left ventricular assist device recipients with positive video capsule endoscopy studies
No. Age (yr) 
and Sex
Presentation Endoscopic findings and 
interval prior to VCE (d)
VCE findings Endoscopic findings and 
interval after VCE (d)
Recurrent bleeding and 
interval after VCE (mo)
Management for 
recurrent  bleeding
1 62 M Anemia Rectal polyp (2) Gastric ulcer N/A Melena (21) EGD: GU with visible 
vessel s/p hemoclip




PE: Gastritis (2) No N/A




N/A Melena (1.7) PE: Bleeding jejunal 
angiodysplasia s/p 
APC




PE: Bleeding jejunal 
angiodysplasia s/p APC + 
hemoclip (2)
No N/A





6 53 M Anemia Duodenitis (4) Stomach and 
small bowel 
bleeding
PE: Clean base GU (2) Melena (0.5) PE: Gastritis and fresh 
blood in duodenum 
without lesions 
identified




N/A Melena (11.4) PE: DLBCL of 
stomach




PE: Normal; SBE: Bleeding 
jejunal angiodysplasia s/p 
APC+ hemoclip (2)









10 59 M Melena Duodenal angiodysplasia 
s/p APC and hemoclip (5)
Small bowel 
bleeding
PE: Bleeding jejunal 
angiodysplasia s/p 
heater probe + APC; 
SBE: Nonbleeding jejunal 












 lesion s/p hemoclip; 
SBE: Bleeding jejunal 
angiodysplasia s/p APC + 
hemoclip (2)
No N/A
12 76 F Melena Normal (4) Colonic bleeding N/A No N/A
APC: Argon plasma coagulation; C-scope: Colonoscopy; DLBCL: Diffuse large B-cell lymphoma; EGD: Esophagogastroduodenoscopy; F: Female; GU: 
Gastric ulcer; M: Male; N/A: Not applicable; PE: Push enteroscopy; SBE: Single balloon enteroscopy; VCE: Video capsule endoscopy.
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other endoscopies performed, may improve the 
diagnostic yield of VCE in this population. 
In a general population with OGIB, > 80% of the 
bleeding sites are in the small bowel[11]. The most 
common location of positive VCE finding in our LVAD 
patients with OGIB is also small bowel (75%). The 
most common finding of positive VCE in our study was 
small bowel bleeding without the cause of bleeding 
identified, whereas small bowel angiodysplasia was 
the second most common finding. The source of 
bleeding can be difficult to identify by VCE in the 
setting of active bleeding since blood can obscure 
visualization and VCE cannot clear the visual field 
with water irrigation. Nevertheless, we surmise that 
angiodysplasia is the most likely cause of GIB in those 
with small bowel bleeding without lesions identified 
given that it has been shown to be the most common 
cause of GIB in LVAD patients[6,7,22]. Indeed, 3 patients 
with small bowel bleeding without lesion identified on 
VCE were later found to have bleeding small bowel 
angiodysplasias on subsequent enteroscopies. Of note, 
in our study 25% of positive VCE findings were within 
reach of EGD or colonoscopy, underscoring the elusive 
nature of these lesions and the importance of repeat 
examinations if necessary.
Our study is the first to report recurrent GIB 
rate in LVAD recipients after VCE. Although LVAD is 
thought to predispose patients to GIB through various 
mechanisms, the recurrent GIB rate (53%) in our LVAD 
population is similar to OGIB in non-LVAD patients[31]. 
Furthermore, there was no difference in the rate of 
recurrent GIB, the number of endoscopies performed 
after VCE, and the mortality rate, whether VCE studies 
were positive or negative. Even among patients with 
a positive VCE, further endoscopic intervention did 
not affect recurrent bleeding- the recurrent bleeding 
rate was 50% regardless of endoscopic intervention 
(Table 3). On the other hand, the negative VCE study 
in our cohort was not associated with lower recurrent 
bleeding rate. It is possible that OGIB may merely be a 
reflection of the underlying condition or hemodynamics 
of LVAD patients, and endoscopic procedures do not 
necessarily impact their natural courses. Endoscopic 
evaluation or therapy in this population therefore 
should be used judiciously, especially given that 
medical therapy with thalidomide or Octreotide 
has recently been reported to be effective in LVAD 
recipients with OGIB[32,33]. Further study is required to 
identify the characteristics of patients who may benefit 
from endoscopic intervention vs supportive care. 
Of the 12 patients with positive VCE studies, only 
6 patients had subsequent endoscopic procedures 
because the other 6 patients had no further GI 
bleeding and their hemoglobin had stabilized, again 
indicating a dissociation of VCE findings with patients’ 
clinical courses. Given that only 50% of patients with 
positive VCE had persistent GIB requiring further 
endoscopic intervention, one possible approach to 
treat LVAD recipients with OGIB based on our finding 
is to defer VCE and endoscopies until persistent GIB 
is observed. The current health care environment 
creates tremendous pressure on hospitals to shorten 
patients’ stay and expedite diagnostic procedures 
and treatment. For certain patients in this population, 
however, it may be more cost-effective to observe and 
provide supportive medical care without endoscopies. 
Future studies are needed to test this hypothesis 
and to determine which subset of LVAD recipients 
with OGIB would benefit from VCE and subsequent 
endoscopies.
None of LVAD recipients in this study died from 
GIB, consistent with a prior report[34]. All 4 patients 
who received heart transplantation in our study 
did not have recurrent bleeding episodes during 
the study period, which is similar to the result in a 
recent systematic review that reported 12 patients 
without recurrent GIB after heart transplantation[7]. 
All together, the data indicates that the changes of 
physiology and hemodynamics associated with LVAD 
are the causes of GIB, and this process and GIB can 
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Table 4  Previous studies of video capsule endoscopy in left ventricular assist device recipients
Study and the year published No. of VCE Diagnostic yield (%) Findings Remarks
Girelli et al[18], 2006   1 N/A No bleeding identified No follow up reported
Garatti et al[15], 2006   1 N/A No bleeding identified No recurrent GIB; received heart 
transplantation
Seow et al[17], 2006   1 N/A Duodenal and jejunal angiodysplasia Push enteroscopy + Octreotide + Sucralfate; 
no follow up reported
Fenkel et al[16], 2007   1 N/A Small bowel angiodysplasia No intervention; no follow up reported
Daas et al[14], 2008   1 N/A Mid-small bowel active bleeding Intraoperative enteroscopy;
no follow up reported
Bechtel et al[19], 2010   1 N/A Bleeding in cecum Colonoscopy; no follow up reported
Elmunzer et al[6], 2011 13 4 (30.8) 3 jejunal angiodysplasias, 1 duodenal 
Dieulafoy’s lesion
1 recurrent bleeding from the same lesion
Meyer et al[22], 2012   5 4 (80.0) 2 jejunal angiodysplasia, 1 cecal ulcer, 1 
jejunal mass
1 colonoscopy; 2 SBE; 1 angiography; no 
follow up reported
Tarzia et al[13], 2013   1 N/A Small bowel angiodysplasia and small 
bowel Dieulafoy’s lesion
DBE; no follow up reported
DBE: Double balloon enteroscopy; GIB: Gastrointestinal bleeding; N/A: Not applicable; SBE: Single balloon enteroscopy; VCE: Video capsule endoscopy.
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be reversed when LVAD is removed. Consistent with 
this concept, a previous study found that all LVAD 
recipients had reduced high molecular weight von 
Willebrand factor multimers which were normalized 
after patients received heart transplants[35].
Our study has limitations. Given that this is a 
retrospective study from a single tertiary medical 
center, it has weaknesses similar to other retrospective 
studies and should be carefully interpreted or 
generalized. In addition, although this study provides 
the largest series of VCE in LVAD recipients with 
OGIB, the sample size of 30 is still limited. We might 
underestimate the true rate of recurrent bleeding 
because the follow-up duration may not be long 
enough. Lastly, in our study VCE were interpreted by 
several gastroenterologists and the management of 
patients was not standardized. These variations may 
affect the results of our study. 
In conclusion, our study shows that VCE can be 
safely performed in LVAD recipients with OGIB and 
with a 40% diagnostic yield. However, the results of 
VCE and the subsequent management driven by VCE 
did not affect the rate of recurrent GIB. Endoscopic 
intervention thus should be used judiciously in this 
patient population. An observation-and-supportive care 
approach could be an alternative way to treat LVAD 
patients with OGIB. Future studies should answer 
the questions of what subset of LVAD recipients with 
OGIB would benefits from endoscopic therapy, and 
what the most cost-effective way is to take care of this 
challenging group of patients.
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